iShares US Power Infrastructure ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares US Power Infrastructure ETF trades at $25.44 (market cap $446.54M), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 22.6× iShares US Power Infrastructure ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares US Power Infrastructure ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Power Infrastructure ETF for 14 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| POWR | XBI | |
|---|---|---|
Market Cap | $446.54M | $10.11B |
Volume | 160,852 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $28.22 | $169.55 |
52-Week Low | $23.20 | $104.99 |
Typical Hold Time | 14 Days | 38 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Trailing returns across standard periods
iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →